HALF MOON BAY, Calif., Dec. 15 /PRNewswire/ -- Saegis Pharmaceuticals, Inc., a biopharmaceutical company focused on developing medicines that protect and enhance memory and cognition, announced today that Ann Neale has joined the company as Vice President, Clinical Operations. In this newly-created role, Ms. Neale will be responsible for the strategic oversight of Saegis' clinical development programs.
"Ann's expertise in the design, implementation and management of clinical trials will be invaluable to the continued successful execution of Saegis' broad clinical strategy," said Rodney Pearlman, Ph.D., President and CEO of Saegis. "Saegis is developing several exciting first-in-class therapeutics addressing serious neurological disorders such as Alzheimer's disease, mild cognitive impairment and schizophrenia. Saegis' lead product, SGS742, being developed for mild to moderate Alzheimer's disease, entered into a large multi-center Phase II clinical trail in the US this year, with results expected in the middle of 2005."
Ms. Neale brings to Saegis more than 15 years of experience in the clinical design and development area with expertise in managing complex clinical programs across multiple therapeutic areas. Prior to joining Saegis, Ms. Neale was the Senior Director, Development Planning and Operations for ARYx Therapeutics where she was responsible for program development and clinical oversight of pre-clinical compounds from filing Investigational New Drug (IND) applications through Phase II clinical development. Prior to her position at ARYx, Ms. Neale co-founded WinPharm Associates, an international development consulting firm, where she was responsible for strategic planning, clinical protocol development and operational oversight for multiple client companies and new therapeutic programs. Prior to founding her consulting company, Ms. Neale held clinical positions of increasing responsibility at Mimetix, Applied Immune Sciences and Syntex. Ms. Neale has clinical experience in critical care and holds a Bachelor of Science Degree in Nursing from the University of Minnesota.
About Saegis Pharmaceuticals
Founded in 1999, Saegis Pharmaceuticals is a pioneer in the development of medicines that protect and enhance the function of the human mind. Saegis Pharmaceuticals is building a portfolio of compounds with activity against a range of disorders of the brain and central nervous system, including Alzheimer's disease, mild cognitive impairment, and cognitive impairment associated with schizophrenia, through strategic licensing, development partnerships and internal discovery programs. Currently the Company has three orally-available small molecule compounds in clinical development, two of which have already demonstrated efficacy and safety in humans. Privately held, Saegis has received investment support from Versant Ventures, Technology Partners, Sofinnova Ventures (U.S.), Sofinnova Partners (Paris), Polaris Venture Partners, NeuroVentures, the Stanley Medical Research Institute and Novartis Pharma AG. For more information, visit http://www.saegispharma.com/.
Saegis Pharmaceuticals, Inc.
CONTACT: Jack Anthony of Saegis Pharmaceuticals, Inc., +1-650-560-0210,ext. 259, or email@example.com; or Karen L. Bergman, +1-650-575-1509,or Michelle Corral, +1-415-794-8662, both of BCC Partners, for SaegisPharmaceuticals, Inc.